Investigating the Role of Skeletal Muscle Dysfunction on Dyspnea and Exercise Intolerance in Interstitial Lung Disease

Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Dyspnea (i.e. breathlessness) and exercise intolerance are common symptoms for patients with interstitial lung disease (ILD), yet it is not known why. It has been suggested that muscle dysfunction may contribute to dyspnea and exercise intolerance in ILD. Our study aims to: i) examine differences in the structure and function of the leg muscles in ILD patients, ii) determine if leg muscle fatigue contributes to dyspnea and exercise limitation in patients with ILD, and iii) determine the effects of breathing extra oxygen on leg muscle fatigue, as well as ability to exercise in ILD patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 80
Healthy Volunteers: t
View:

• Age 40-80 years (inclusive)

• A multidisciplinary diagnosis of idiopathic pulmonary fibrosis (IPF), idiopathic fibrotic nonspecific interstitial pneumonia (NSIP), chronic hypersensitivity pneumonitis (HP), or unclassifiable ILD with a differential diagnosis that consists of the above diagnoses

• Fibrosis on high resolution computed tomography (HRCT): honeycombing, reticulation, or traction bronchiectasis

• Appropriate candidate for pulmonary rehabilitation

• 6 minute walk distance 50m or more

• Oxygen saturation ≥ 92% by pulse oximetry at rest while breathing room air

• Clinically stable for the preceding 6 weeks

• Can fluently read and write in English

• Age 40-80 (inclusive)

• Normal pulmonary function (80-120% predicted)

• No lung or cardiovascular disease

• Can fluently read and write in English

Locations
Other Locations
Canada
St. Paul's Hospital
RECRUITING
Vancouver
Contact Information
Primary
Olivia Ferguson, MSc
Olivia.Ferguson@hli.ubc.ca
1-604-806-8835
Backup
Satvir S Dhillon, MSc
Satvir.Dhillon@hli.ubc.ca
1-604-806-8835
Time Frame
Start Date: 2024-08-07
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 40
Treatments
Experimental: Hyperoxia
During exercise on visit 4, participants in both groups (i.e., ILD patients and controls) will breathe supplemental oxygen (i.e., 60% oxygen) during constant-load exercise.
Placebo_comparator: Healthy Controls
During exercise on visit 3, participants in both groups (i.e., ILD patients and controls) will breathe ambient air (i.e., 20.93% oxygen) during constant-load exercise.
Sponsors
Leads: University of British Columbia

This content was sourced from clinicaltrials.gov